[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.117. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
1.
Geenen MM, Cardous-Ubbink MC, Kremer LC,  et al.  Medical assessment of adverse health outcomes in long-term survivors of childhood cancer.  JAMA. 2007;297(24):2705-271517595271PubMedGoogle ScholarCrossref
2.
Oeffinger KC, Mertens AC, Sklar CA,  et al.  Chronic health conditions in adult survivors of childhood cancer.  N Engl J Med. 2006;355(15):1572-158217035650PubMedGoogle ScholarCrossref
3.
Sun CL, Francisco L, Kawashima T,  et al.  Prevalence and predictors of chronic health conditions after hematopoietic cell transplantation.  Blood. 2010;116(17):3129-313920656930PubMedGoogle ScholarCrossref
4.
Dowling E, Yabroff KR, Mariotto A, McNeel T, Zeruto C, Buckman D. Burden of illness in adult survivors of childhood cancers.  Cancer. 2010;116(15):3712-372120564096PubMedGoogle ScholarCrossref
5.
Rebholz CE, Reulen RC, Toogood AA,  et al.  Health care use of long-term survivors of childhood cancer.  J Clin Oncol. 2011;29(31):4181-418821947833PubMedGoogle ScholarCrossref
6.
Hudson MM, Ness KK, Nolan VG,  et al.  Prospective medical assessment of adults surviving childhood cancer.  Pediatr Blood Cancer. 2011;56(5):825-83621370418PubMedGoogle ScholarCrossref
7.
Ojha RP, Oancea SC, Ness KK,  et al.  Assessment of potential bias from non-participation in a dynamic clinical cohort of long-term childhood cancer survivors.  Pediatr Blood Cancer. 2013;60(5):856-86423024097PubMedGoogle ScholarCrossref
8.
Children's Oncology Group.  Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 3.0. http://www.survivorshipguidelines.org. Accessed January 28, 2013
9.
 Cancer Therapy Evaluation Program (CTEP). National Cancer Institute website. http://dctd.cancer.gov/ProgramPages/CTEP/. Accessed May 6, 2013
10.
Rückinger S, von Kries R, Toschke AM. An illustration of and programs estimating attributable fractions in large scale surveys considering multiple risk factors.  BMC Med Res Methodol. 2009;9:719166593PubMedGoogle ScholarCrossref
11.
Allison PD. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute Inc; 1995
12.
Staba Hogan MJ, Ma X, Kadan-Lottick NS. New health conditions identified at a regional childhood cancer survivor clinic visit.  Pediatr Blood Cancer. 2013;60(4):682-68723023769PubMedGoogle ScholarCrossref
13.
Landier W, Armenian SH, Lee J,  et al.  Yield of screening for long-term complications using the Children's Oncology Group long-term follow-up guidelines.  J Clin Oncol. 2012;30(35):4401-440823091100PubMedGoogle ScholarCrossref
14.
Wasilewski-Masker K, Mertens AC, Patterson B, Meacham LR. Severity of health conditions identified in a pediatric cancer survivor program.  Pediatr Blood Cancer. 2010;54(7):976-98220108334PubMedGoogle Scholar
15.
Hudson MM, Neglia JP, Woods WG,  et al.  Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies.  Pediatr Blood Cancer. 2012;58(3):334-34322038641PubMedGoogle ScholarCrossref
16.
Green DM, Kun LE, Matthay KK,  et al.  Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors [published online February 15, 2013].  Pediatr Blood CancerGoogle Scholar
17.
Asbell PA, Dualan I, Mindel J, Brocks D, Ahmad M, Epstein S. Age-related cataract.  Lancet. 2005;365(9459):599-60915708105PubMedGoogle Scholar
18.
Frisina RD. Age-related hearing loss: ear and brain mechanisms.  Ann N Y Acad Sci. 2009;1170:708-71719686217PubMedGoogle ScholarCrossref
19.
Glisky EL. Changes in cognitive function and human aging. In: Riddle DR, ed. Brain Aging: Models, Methods, and Mechanisms. Boca Raton, FL: CRC Press; 2007
20.
Marin-Garcia J, Goldentha MJ, Moe GW. Cardiomyopathy and heart failure in aging. In: Marin-Garcia J, ed. Aging and the Heart. Secaucus, NJ: Springer US; 2008:209-238
21.
Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH. Cancer survivors: a booming population.  Cancer Epidemiol Biomarkers Prev. 2011;20(10):1996-200521980007PubMedGoogle ScholarCrossref
22.
Armstrong GT, Reddick WE, Peterson RC,  et al.  Evaluation of memory impairment in aging adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiotherapy [published online April 12, 2013].  J Natl Cancer InstGoogle Scholar
23.
de Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors.  Lancet Oncol. 2010;11(2):193-20320152771PubMedGoogle ScholarCrossref
24.
Mertens AC, Liu Q, Neglia JP,  et al.  Cause-specific late mortality among 5-year survivors of childhood cancer.  J Natl Cancer Inst. 2008;100(19):1368-137918812549PubMedGoogle ScholarCrossref
Original Contribution
Clinician's Corner
June 12, 2013

Clinical Ascertainment of Health Outcomes Among Adults Treated for Childhood Cancer

Author Affiliations

Author Affiliations: Departments of Oncology (Drs Hudson and Mulrooney), Epidemiology and Cancer Control (Drs Hudson, Ness, Gurney, Mulrooney, Chemaitilly, Krull, Green, Armstrong, and Robison and Ms Jones), Pediatric Medicine (Dr Chemaitilly), Hematology (Dr Nottage), and Biostatistics (Dr Srivastava), St Jude Children's Research Hospital and the University of Tennessee College of Medicine, Memphis; and Memorial Sloan-Kettering Cancer Center, New York, New York (Dr Sklar).

JAMA. 2013;309(22):2371-2381. doi:10.1001/jama.2013.6296
Abstract

Importance Adult survivors of childhood cancer are known to be at risk for treatment-related adverse health outcomes. A large population of survivors has not been evaluated using a comprehensive systematic clinical assessment to determine the prevalence of chronic health conditions.

Objective To determine the prevalence of adverse health outcomes and the proportion associated with treatment-related exposures in a large cohort of adult survivors of childhood cancer.

Design, Setting, and Participants Presence of health outcomes was ascertained using systematic exposure–based medical assessments among 1713 adult (median age, 32 [range, 18-60] years) survivors of childhood cancer (median time from diagnosis, 25 [range, 10-47] years) enrolled in the St Jude Lifetime Cohort Study since October 1, 2007, and undergoing follow-up through October 31, 2012.

Main Outcomes and Measures Age-specific cumulative prevalence of adverse outcomes by organ system.

Results Using clinical criteria, the crude prevalence of adverse health outcomes was highest for pulmonary (abnormal pulmonary function, 65.2% [95% CI, 60.4%-69.8%]), auditory (hearing loss, 62.1% [95% CI, 55.8%-68.2%]), endocrine or reproductive (any endocrine condition, such as hypothalamic-pituitary axis disorders and male germ cell dysfunction, 62.0% [95% CI, 59.5%-64.6%]), cardiac (any cardiac condition, such as heart valve disorders, 56.4% [95% CI, 53.5%-59.2%]), and neurocognitive (neurocognitive impairment, 48.0% [95% CI, 44.9%-51.0%]) function, whereas abnormalities involving hepatic (liver dysfunction, 13.0% [95% CI, 10.8%-15.3%]), skeletal (osteoporosis, 9.6% [95% CI, 8.0%-11.5%]), renal (kidney dysfunction, 5.0% [95% CI, 4.0%-6.3%]), and hematopoietic (abnormal blood cell counts, 3.0% [95% CI, 2.1%-3.9%]) function were less common. Among survivors at risk for adverse outcomes following specific cancer treatment modalities, the estimated cumulative prevalence at age 50 years was 21.6% (95% CI, 19.3%-23.9%) for cardiomyopathy, 83.5% (95% CI, 80.2%-86.8%) for heart valve disorder, 81.3% (95% CI, 77.6%-85.0%) for pulmonary dysfunction, 76.8% (95% CI, 73.6%-80.0%) for pituitary dysfunction, 86.5% (95% CI, 82.3%-90.7%) for hearing loss, 31.9% (95% CI, 28.0%-35.8%) for primary ovarian failure, 31.1% (95% CI, 27.3%-34.9%) for Leydig cell failure, and 40.9% (95% CI, 32.0%-49.8%) for breast cancer. At age 45 years, the estimated cumulative prevalence of any chronic health condition was 95.5% (95% CI, 94.8%-98.6%) and 80.5% (95% CI, 73.0%-86.6%) for a serious/disabling or life-threatening chronic condition.

Conclusions and Relevance Among adult survivors of childhood cancer, the prevalence of adverse health outcomes was high, and a systematic risk-based medical assessment identified a substantial number of previously undiagnosed problems that are more prevalent in an older population. These findings underscore the importance of ongoing health monitoring for adults who survive childhood cancer.

×